BioNeutra Global Corporation
TSX VENTURE : BGA

BioNeutra Global Corporation

May 03, 2016 18:12 ET

BioNeutra Global Corporation Announces Appointment of Darren Kostiw as Vice President of Sales and Marketing

EDMONTON, ALBERTA--(Marketwired - May 3, 2016) - BioNeutra Global Corporation ("BioNeutra" or the "Company") (TSX VENTURE:BGA) is pleased to announce the appointment of Mr. Darren J. Kostiw as the Vice President of Sales and Marketing of the Company's wholly-owned subsidiary BioNeutra North America Inc.

Mr. Darren Kostiw joins BioNeutra with nearly twenty years of experience in sales, marketing and management responsibility. He has held such positions in regional as well as in large multinational companies and has extensive experience with implementing new strategies. Mr. Kostiw has received numerous accolades over the years including Salesman of the Year and for the Highest Sales of Imported Products for a large ingredients and chemicals company.

Mr. Kostiw holds a Bachelor of Science and a Bachelor of Science with Specialization in environmental physical sciences.

"We are very pleased and delighted to have Darren join our team at BioNeutra. Mr. Kostiw's many years of experience with developing new sales and marketing strategies will be a great asset to BioNeutra in the continued growth of the Company," said Bill Smith, Chairman and Senior Vice President.

As Vice President of Sales and Marketing, Mr. Kostiw will be responsible for developing and executing the Company's sales and marketing initiatives, identify market opportunities and fulfill market needs, ensure delivery of quality solutions and meet short and long term business goals.

About BioNeutra

BioNeutra is in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages, with a focus on IMOs.

The Company's lead product, VitaFiber™, is an advanced functional and health food and beverage ingredient scientifically made from natural agricultural products, is generally regarded as safe (GRAS) by the U.S. Food & Drug Administration, and is European Food Safety Authority and Health Canada approved as a novel food ingredient. VitaFiber™ is naturally sweet and lower in calories than regular sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health.

The Company produces VitaFiber™ using its patented processes that naturally transform starch molecules from agriculture cereal crops including corn, wheat, barley, potato, or tapioca into the functional health molecules of IMO. The VitaFiber™ manufacturing process is based upon a natural enzymatic conversion of starch molecules without any chemical modification involved, making VitaFiber™ a natural food and beverage ingredient. VitaFiber™ is also non-GMO, vegan-friendly, gluten-free, Kosher and Halal certified and available as certified organic.

The Company's customers include a mix of small and medium enterprises and a number of high-profile food and beverage manufacturers in Canada, the U.S., Europe, the United Kingdom, and Mexico. VitaFiber™ is also available for retail purchase across the globe through Amazon.com and other direct-to-consumer retailers.

Further information about BioNeutra is available on the Company's website at www.bioneutra.ca and the SEDAR website at www.sedar.com.

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

Contact Information